NICE to re-review Ferring's prostate cancer drug
This article was originally published in Scrip
Executive Summary
NICE, the HTA body for England and Wales, has agreed to re-review Ferring Pharmaceuticals' Firmagon (degarelix) as an option for treating advanced hormone-dependent prostate cancer.